

## **HDAC1 Inhibitor Screening Assay Kit**

Item No. 10011564



**Customer Service** 800.364.9897 \* **Technical Support** 888.526.5351  
[www.caymanchem.com](http://www.caymanchem.com)

# TABLE OF CONTENTS

GENERAL INFORMATION	3	Materials Supplied
	4	Precautions
	4	If You Have Problems
	4	Storage and Stability
	4	Materials Needed but Not Supplied
INTRODUCTION	5	Background
	5	About This Assay
PRE-ASSAY PREPARATION	6	Reagent Preparation
ASSAY PROTOCOL	7	Plate Set Up
	9	Performing the Assay
ANALYSIS	10	Calculations
	11	Performance Characteristics
RESOURCES	12	Troubleshooting
	13	References
	13	Related Products
	14	Warranty and Limitation of Remedy
	15	Plate Template
	16	Notes

# GENERAL INFORMATION

## Materials Supplied\*

Kit will arrive packaged as a -80°C kit, for best results, remove components and store as stated below.

Item Number	Item	Quantity	Storage
10006389	HDAC Assay Buffer (10X)	1 vial	-20°C
10011618	HDAC1 (human recombinant)	1 vial	-80°C
10006391	HDACTrichostatin A	1 vial	-20°C
10006392	HDAC Substrate	1 vial	-20°C
400017	96-Well Plate (Black)	1 plate	Room temperature
10006394	HDAC Developer	2 vials	-20°C
400012	96-Well Cover Sheet	1 cover	Room temperature

If any of the items listed above are damaged or missing, please contact our Customer Service department at (800) 364-9897 or (734) 971-3335. We cannot accept any returns without prior authorization.

*Sold under license from CycLex® Co., Ltd (Patent Nos. EP 1243658, US 7033778, US 7256013, and JP 4267043).*



**WARNING:** This product is for laboratory research use only: not for administration to humans. Not for human or veterinary diagnostic or therapeutic use.

## Precautions

**Please read these instructions carefully before beginning this assay. For research use only. Not for human or diagnostic use.**

## If You Have Problems

### Technical Service Contact Information

**Phone:** 888-526-5351 (USA and Canada only) or 734-975-3888

**Fax:** 734-971-3641

**Email:** techserv@caymanchem.com

**Hours:** M-F 8:00 AM to 5:30 PM EST

In order for our staff to assist you quickly and efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).

## Storage and Stability

This kit will perform as specified if stored as directed at -80°C and used before the expiration date indicated on the outside of the box.

## Materials Needed But Not Supplied

1. A fluorometer capable of measuring fluorescence using excitation wavelengths of 340-360 nm and emission wavelengths of 440-465 nm.
2. Adjustable pipettes and a repeating pipettor.
3. A source of UltraPure water (Milli-Q or HPLC-grade water).

## INTRODUCTION

### Background

Nucleosomes, which fold chromosomal DNA, contain two molecules each of the core histones H2A, H2B, H3, and H4. Almost two turns of DNA are wrapped around this octameric core, which represses transcription.<sup>1</sup> The histone amino termini extend from the core, where they can be modified post-translationally by acetylation, phosphorylation, ubiquitination, and methylation, affecting their charge and function.

Acetylation of the  $\epsilon$ -amino groups of specific histone lysines is catalyzed by histone acetyltransferases (HATs) and correlates with an open chromatin structure and gene activation. Histone deacetylases (HDACs) catalyze the hydrolytic removal of acetyl groups from histone lysine residues and correlates with chromatin condensation and transcriptional repression.<sup>2,3</sup> Therefore, HDAC inhibition results in transcriptional activation through the conformational relaxation of DNA. Changes in the transcription of key genes has linked HDAC inhibitors to blocking angiogenesis and cell cycling, and promoting apoptosis and differentiation. By targeting these key components of tumor proliferation, HDAC inhibitors are currently being explored as potential anticancer agents.<sup>4-6</sup>

### About This Assay

Cayman's HDAC1 Inhibitor Screening Assay Kit provides a fast, fluorescent-based method for screening HDAC1 inhibitors. The procedure requires only two easy steps, both performed in the same microplate. In the first step, an acetylated lysine substrate is incubated with HDAC1. Deacetylation sensitizes the substrate such that treatment with the HDAC developer in the second step releases a fluorescent product. The fluorophore can be easily analyzed using a fluorescence plate reader or a fluorometer with excitation wavelengths of 340-360 nm and emission wavelengths of 440-465 nm.

## PRE-ASSAY PREPARATION

### Reagent Preparation

#### 1. HDAC Assay Buffer (10X) - (Item No. 10006389)

Dilute 5 ml of Assay Buffer concentrate with 45 ml of UltraPure water. This final Assay Buffer [25 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, and 1 mM  $MgCl_2$ ] should be used in the assay. It is used for diluting HDAC1 and for dissolving the HDAC Developer. The diluted buffer is stable for six months at 4°C.

#### 2. HDAC1 (human recombinant) - (Item No. 10011618)

The vial contains 125 µl of partially purified human recombinant HDAC1. Dilute 100 µl of HDAC1 with 900 µl of diluted Assay Buffer. Some turbidity is expected. The diluted HDAC1 is stable for four hours when stored on ice. If not assaying the entire plate, then adjust the enzyme volume accordingly.

#### 3. HDAC Trichostatin A - (Item No. 10006391)

The vial contains 250 µl of 0.21 mM Trichostatin A. Trichostatin A is an HDAC inhibitor.

#### 4. HDAC Substrate - (Item No. 10006392)

The vial contains 1.2 ml of 3.4 mM acetylated fluorometric substrate in dimethylsulfoxide (DMSO). The solution is ready to use as supplied. *NOTE: The  $K_m$  value for the HDAC Substrate is 100 µM. The final concentration of HDAC Substrate in the assay, as described, is 200 µM. This concentration may be reduced by dilution with DMSO at the user's discretion, particularly when assaying for competitive inhibitors.*

#### 5. HDAC Developer - (Item No. 10006394)

The vial contains the HDAC developer. Dissolve the contents of the vial in 4 ml of diluted Assay Buffer and store on ice. Add 100 µl of Trichostatin A (Item No. 10006391) to the reconstituted Developer. One vial of Developer will develop the entire plate. The reconstituted Developer is stable for two hours.

## ASSAY PROTOCOL

### Plate Set Up

There is no specific pattern for using the wells on the plate. However, it is necessary to have three wells designated as 100% initial activity and three wells designated as background wells. We suggest that each inhibitor sample be assayed in triplicate and that you record the contents of each well on the template sheet provided (See page 15). A typical layout of samples and inhibitors to be measured in triplicate is given in Figure 1.

	1	2	3	4	5	6	7	8	9	10	11	12
A	BW	BW	BW	7	7	7	15	15	15	23	23	23
B	A	A	A	8	8	8	16	16	16	24	24	24
C	1	1	1	9	9	9	17	17	17	25	25	25
D	2	2	2	10	10	10	18	18	18	26	26	26
E	3	3	3	11	11	11	19	19	19	27	27	27
F	4	4	4	12	12	12	20	20	20	28	28	28
G	5	5	5	13	13	13	21	21	21	29	29	29
H	6	6	6	14	14	14	22	22	22	30	30	30

BW - Background Wells

A - 100% Initial Activity Wells

1-30 - Inhibitor Wells

Figure 1. Sample plate format

### Pipetting Hints

- It is recommended that an adjustable pipette be used to deliver reagents to the wells.
- Before pipetting each reagent, equilibrate the pipette tip in that reagent (*i.e.*, slowly fill the tip and gently expel the contents, repeat several times).
- Do not expose the pipette tip to the reagent(s) already in the well.

### General Information

- The final volume of the assay is 210  $\mu$ l in all the wells.
- Use the diluted Assay Buffer in the assay.
- All reagents except HDAC1 and Developer must be equilibrated to room temperature before beginning the assay.
- It is not necessary to use all the wells on the plate at one time.
- If the appropriate inhibitor dilution is not known, it may be necessary to assay at several dilutions.
- We recommend assaying samples in triplicate, but it is the user's discretion to do so.
- Thirty inhibitor samples can be assayed in triplicate or forty-six in duplicate.
- The assay temperature is 37°C.
- Monitor the fluorescence with an excitation wavelength of 340-360 nm and an emission wavelength of 440-465 nm.

### Performing the Assay

1. **100% Initial Activity Wells** - add 140  $\mu$ l of Assay Buffer, 10  $\mu$ l of diluted HDAC1, and 10  $\mu$ l of solvent (the same solvent used to dissolve the inhibitor) to three wells.
2. **Background Wells** - add 150  $\mu$ l of Assay Buffer and 10  $\mu$ l of solvent (the same solvent used to dissolve the inhibitor) to three wells.
3. **Inhibitor Wells** - add 140  $\mu$ l of Assay Buffer, 10  $\mu$ l of diluted HDAC1, and 10  $\mu$ l of inhibitor\* to three wells.
4. Initiate the reactions by adding 10  $\mu$ l of HDAC Substrate to all the wells being used.
5. Cover the plate with the plate cover and incubate on a shaker for 30 minutes at 37°C.
6. Remove the plate cover and add 40  $\mu$ l of Developer. Cover the plate with the plate cover and incubate for 15 minutes at room temperature.
7. Remove the plate cover and read the fluorescence using an excitation wavelength of 340-360 nm and an emission wavelength of 440-465 nm. It may be necessary to adjust the gain setting on the instrument to allow for the measurement of all the samples. The development is stable for 30 minutes.


\*Inhibitors can be dissolved in Assay Buffer, ethanol, methanol, or DMSO and should be added to the assay in a final volume of 10  $\mu$ l. In the event that the appropriate concentration of inhibitor needed for HDAC inhibition is completely unknown, we recommend that several dilutions of the inhibitor be assayed.

## ANALYSIS

### Calculations

1. Determine the average fluorescence of each sample.
2. Subtract the fluorescence of the background wells from all wells on the plate.
3. Determine the percent inhibition for each sample. To do this, subtract each inhibitor sample value from the 100% initial activity sample value. Divide the result by the 100% initial activity value and then multiply by 100 to give the percent inhibition.
4. Either graph the Percent Inhibition or Percent Initial Activity as a function of the inhibitor concentration to determine the  $IC_{50}$  value (concentration at which there was 50% inhibition). An example of HDAC1 inhibition by Trichostatin A is shown in Figure 2, on page 11.

$$\% \text{ Inhibition} = \left[ \frac{\text{Initial Activity} - \text{Sample}}{\text{Initial Activity}} \right] \times 100$$



**Figure 2. Inhibition of HDAC1 by Trichostatin A ( $IC_{50} = 12$  nM; final concentration of HDAC Substrate is 200  $\mu$ M).**

### Performance Characteristics

#### Precision:

When a series of eight HDAC1 measurements were performed on the same day, the intra-assay coefficient of variation was 2.8%. When a series of eight HDAC1 measurements were performed on five different days under the same experimental conditions, the inter-assay coefficient of variation was 2.7%.

## RESOURCES

### Troubleshooting

Problem	Possible Causes	Recommended Solutions
Erratic values; dispersion of duplicates/triplicates	A. Poor pipetting/technique B. Bubble in the well(s)	A. Be careful not to splash the contents of the wells B. Carefully tap the side of the plate with your finger to remove bubbles
No fluorescence above background is seen in the inhibitor wells	Inhibitor concentration is too high and inhibited all of the enzyme activity	Reduce the concentration of the inhibitor and re-assay
Fluorescence value was at the maximal level in the sample wells	A. The sample is too concentrated B. The Gain setting is set too high	Make sure you diluted the HDAC1 correctly. Set the gain to a lower setting and measure the fluorescence
No inhibition was seen with the inhibitor	A. The inhibitor concentration is not high enough B. The compound is not an inhibitor of the enzyme	Increase the inhibitor concentration and re-assay

## References

1. Grunstein, M. Histone acetylation in chromatin structure and transcription. *Nature* **389**, 349-352 (1997).
2. Strahl, B.D. and Allis, D. The language of covalent histone modifications. *Nature* **403**, 41-45 (2000).
3. Cheung, W.L., Briggs, D.B., and Allis, C.D. Acetylation and chromosomal functions. *Curr. Opin. Cell Biol.* **12**, 326-333 (2000).
4. Kwon, H.J., Kim, M.S., Kim, M.J., *et al.* Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. *Int. J. Cancer* **97**, 290-296 (2002).
5. Suenaga, M., Soda, H., Oka, M., *et al.* Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. *Int. J. Cancer* **97**, 621-625 (2002).
6. Johnstone, R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. *Nature Reviews Drug Discover* **1**, 287-299 (2002).

## Related Products

CAY10398 - Item No. 89740  
 CAY10433 - Item No. 10005019  
 CAY10591 - Item No. 10009797  
 HAT Inhibitor Screening Assay Kit - Item No. 10006515  
 HDAC Cell-Based Activity Assay Kit - Item No. 600150  
 HDAC Fluorometric Activity Assay Kit - Item No. 10011563  
 HDAC1 (human recombinant) - Item No. 10009231  
 HDAC1 Polyclonal Antibody - Item No. 13491  
 HDAC8 Inhibitor Screening Assay Kit - Item No. 700230  
 PAD4 Inhibitor Screening Assay Kit - Item No. 700560  
 SIRT1 Direct Fluorescent Screening Assay Kit - Item No. 10010401  
 SIRT1 FRET-Based Screening Assay Kit - Item No. 10010991  
 SIRT3 Direct Fluorescent Screening Assay Kit - Item No. 10011566  
 Splitomicin - Item No. 13168  
 Trichostatin A - Item No. 89730

Warranty and Limitation of Remedy

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will meet our specifications at the time of delivery. Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence. This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer’s **exclusive remedy** and Cayman’s sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman’s option, the replacement, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

12								
11								
10								
9								
8								
7								
6								
5								
4								
3								
2								
1								
	A	B	C	D	E	F	G	H



## NOTES

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine-readable form without prior consent, in writing, from Cayman Chemical Company.

©10/30/2014, Cayman Chemical Company, Ann Arbor, MI, All rights reserved. Printed in U.S.A.